GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Auxilium Pharmaceuticals, Inc. (AUXL) [hlAlert]

Rating:
Underweight
AUXL
down 18.80 %

Auxilium Pharmaceuticals, Inc. (AUXL) downgraded to Underweight by Morgan Stanley

Posted on: Thursday,  Mar 6, 2014  8:25 AM ET by Morgan Stanley

Morgan Stanley rated Underweight Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) on 03/06/2014, when the stock price was $29.61. Since
then, Auxilium Pharmaceuticals, Inc. has gained 23.17% as of 01/29/2015's recent price of $36.47.
If you would have followed this Morgan Stanley's recommendation on AUXL, you would have lost 18.8% of your investment in 329 days.

Auxilium Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets products for urology and sexual health. Auxilium markets Testim 1%, a topical testosterone gel, for the treatment of hypogonadism. Auxilium is developing additional Testim line extensions, as well as other products for urology and sexual health, including an enzyme in Phase II for the treatment of Peyronie's Disease that may also prove useful for the treatment of Dupuytren's Disease.

Morgan Stanley Investment Research is one of the financial industry's dominant thought leaders in equity and fixed-income investing. Our analysts, economists, and strategists have earned this reputation through timely, in-depth analysis of companies, industries, markets, and the world’s economies. Our teams collaborate to assist Morgan Stanley clients with investment decisions, using cash and derivative instruments across major asset classes and geographies.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/6/2014 8:25 AM Sell
None
29.61
as of 10/17/2014
1 Week up  3.58 %
1 Month up  1.76 %
3 Months down  -58.29 %
1 YTD down  -3.44 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/3/2013 8:25 AM Hold
None
15.27
8/21/2012 8:25 AM Sell
None
23.02

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy